Inhibrx Biosciences IncNASDAQ:INBX
- LAST PRICE15.5200
- TODAY'S CHANGE (%)0.1900 (1.2394%)
- Bid / Lots7.8500/ 1
- Ask / Lots16.9700/ 1
- Open / Previous Close15.3300 / 15.3300
- Day Range
- 52 Week Range
- Volume55,395
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | INBX |
|---|---|---|
| 09:32 ET | 2292 | 15.33 |
| 09:41 ET | 500 | 15.16 |
| 09:54 ET | 300 | 15.42 |
| 09:56 ET | 100 | 15.5 |
| 10:10 ET | 100 | 15.55 |
| 10:17 ET | 100 | 15.6 |
| 10:21 ET | 100 | 15.595 |
| 10:30 ET | 1200 | 15.59 |
| 10:33 ET | 100 | 15.65 |
| 10:50 ET | 100 | 15.91 |
| 11:06 ET | 100 | 15.93 |
| 11:13 ET | 4262 | 15.87 |
| 11:15 ET | 100 | 15.94 |
| 11:40 ET | 200 | 15.92 |
| 11:49 ET | 120 | 16.006 |
| 11:54 ET | 1150 | 16.05 |
| 11:56 ET | 280 | 16.03 |
| 11:58 ET | 300 | 16.05 |
| 12:00 ET | 1680 | 15.97 |
| 12:02 ET | 200 | 16 |
| 12:03 ET | 500 | 16.0525 |
| 12:07 ET | 1188 | 16.01 |
| 12:12 ET | 581 | 16.005 |
| 12:30 ET | 200 | 16.045 |
| 12:32 ET | 300 | 15.94 |
| 12:34 ET | 100 | 15.94 |
| 12:52 ET | 316 | 16 |
| 12:56 ET | 100 | 16.04 |
| 12:57 ET | 200 | 15.985 |
| 12:59 ET | 300 | 15.855 |
| 01:12 ET | 100 | 15.915 |
| 01:32 ET | 100 | 15.9799 |
| 01:51 ET | 200 | 15.98 |
| 02:08 ET | 432 | 15.905 |
| 02:13 ET | 100 | 15.915 |
| 02:24 ET | 100 | 15.98 |
| 02:26 ET | 100 | 15.935 |
| 02:27 ET | 100 | 15.87 |
| 02:49 ET | 200 | 15.83 |
| 03:21 ET | 276 | 15.71 |
| 03:27 ET | 1800 | 15.7 |
| 03:48 ET | 100 | 15.68 |
| 03:50 ET | 300 | 15.62 |
| 03:52 ET | 1325 | 15.55 |
| 03:56 ET | 4100 | 15.575 |
| 03:57 ET | 600 | 15.58 |
| 03:59 ET | 11141 | 15.52 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Inhibrx Biosciences Inc | 221.9M | 0.1x | --- |
Pyxis Oncology Inc | 221.1M | -2.9x | --- |
Acrivon Therapeutics Inc | 224.9M | -2.6x | --- |
Candel Therapeutics Inc | 224.9M | -4.2x | --- |
Kyverna Therapeutics Inc | 226.5M | 0.0x | --- |
Omeros Corp | 227.2M | -1.2x | --- |
Company Information
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. The Company’s clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that is designed with its proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist, being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor.
Contact Information
- Headquarters
- 11025 N. Torrey Pines Road, Suite 140LA JOLLA, CA, United States 92037
- Phone
- 858-795-4220
- Fax
- 302-636-5454
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $221.9M |
|---|---|
Revenue (TTM) | $1.9M |
Shares Outstanding | 14.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $121.21 |
Book Value | $0.92 |
P/E Ratio | 0.1x |
Price/Sales (TTM) | 119.8 |
Price/Cash Flow (TTM) | 0.1x |
Operating Margin | 89,188.29% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
